SCHEMBL630803

SCHEMBL630803

C=CCC(C)(C)C#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446928 0.78 MAPT (0.31)
SCHEMBL9422309 0.77
SCHEMBL10785172 0.77 MAPT (0.35)
SCHEMBL25712325 0.76
SCHEMBL5992965 0.74
SCHEMBL2160172 0.74
SCHEMBL6052748 0.72
SCHEMBL21138744 0.72
SCHEMBL16830378 0.72
SCHEMBL9765943 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4346204-A HYDROXYLATED DICYCLOPENTADIENE-MALEIC ANHYDRIDE COPOLYMER C Hemische Werke Huls Aktiengesellschaft (DE) 1982-08-24 US claimed
EP-3668863-B1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-03-19 EP disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 US disclosed
CN-111372927-A Tricyclic compounds as histone methyltransferase inhibitors 全球血液疗法股份有限公司 2020-07-03 CN disclosed
EP-3668863-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2020-06-24 EP disclosed
WO-2019036377-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2019-02-21 WO disclosed
US-9783511-B2 Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease LYCERA CORPORATION (US) 2017-10-10 US disclosed
US-9783511-B2 Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease LYCERA CORPORATION (US) 2017-10-10 US disclosed
US-9783511-B2 Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease LYCERA CORPORATION (US) 2017-10-10 US disclosed
EP-2083844-A2 HCV NS3 PROTEASE INHIBITORS Merck & Co., Inc. (US) 2009-08-05 EP disclosed
US-20080262050-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-23 US disclosed
EP-1963292-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-09-03 EP disclosed
WO-2008057208-A2 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2008-05-15 WO disclosed
WO-2007067615-A2 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2007-06-14 WO disclosed
EP-1773849-A1 FUNCTIONALIZED SILICON COMPOUNDS Honeywell International, Inc. (US) 2007-04-18 EP disclosed
WO-2006014367-A1 FUNCTIONALIZED SILICON COMPOUNDS HONEYWELL INTERNATIONAL INC. (US) 2006-02-09 WO disclosed
US-4346204-A HYDROXYLATED DICYCLOPENTADIENE-MALEIC ANHYDRIDE COPOLYMER C Hemische Werke Huls Aktiengesellschaft (DE) 1982-08-24 US disclosed
US-4346204-A HYDROXYLATED DICYCLOPENTADIENE-MALEIC ANHYDRIDE COPOLYMER C Hemische Werke Huls Aktiengesellschaft (DE) 1982-08-24 US disclosed
US-3959269-A TRANQUILIZERS, SEDATIVES SANDOZ, INC. (US) 1976-05-25 US disclosed